Significant Harm From Just
ONE Mercury-Containing Vaccine
A new study found that primates that received just ONE vaccination
containing thimerosal, the mercury-preservative found in many
vaccines including the new swine flu shot, had significant neurological
impairment when compared with those who received a saline solution
injection or no injection at all.
Although the paper is carefully worded and the results reported
modestly, these findings are certain to receive intense scrutiny.
The vast majority of American infants born during the 1990s
received a vaccine formulation similar to the one the thirteen
vaccinated primates received.
Thimerosal-containing vaccines are still routinely administered
to newborn infants in developing countries such as Brazil, and
most influenza vaccines contain thimerosal and are routinely administered
to pregnant women and infants.
The finding that early exposure to potentially toxic vaccine
formulations can cause significant neurodevelopmental delays in
primates has explosive implications for vaccine safety management.
But while Americans are still debating whether to roll up their
sleeves for a swine flu shot, companies have already figured it
out: vaccines are good for business.
Drug companies have sold $1.5 billion worth of swine flu shots,
in addition to the $1 billion for seasonal flu they booked earlier
this year. These inoculations are part of a much wider and rapidly
growing $20 billion global vaccine market.
"The vaccine market is booming," says Bruce Carlson,
spokesperson at market research firm Kalorama, which publishes
an annual survey of the vaccine industry. "It's an enormous
growth area for pharmaceuticals at a time when other areas are
not doing so well," he says, noting that the pipeline for
more traditional blockbuster drugs such as Lipitor and Nexium
As always with pandemic flus, taxpayers are footing the $1.5
billion check for the 250 million swine flu vaccines that the
government has ordered so far and will be distributing free to
doctors, pharmacies and schools. In addition, Congress has set
aside more than $10 billion this year to research flu viruses,
monitor H1N1's progress and educate the public about prevention.
Drugmakers benefit most from the revenues from flu sales, with
Sanofi-Pasteur, Glaxo Smith Kline and Novartis cornering most
of the market.
But some say it's not just drugmakers who stand to benefit. Doctors
collect copayments for special office visits to inject shots,
and there have been assertions that these doctors actually profit
handsomely from these vaccinations..
full list of h1n1 vaccine ingredients, alerts and warnings.
Reference Source 116
October 22, 2009